Unique sequences represent the new frontier in drug development. These small chains of building acids offer significant promise for engaging intractable pathways involved in multiple conditions. Initial studies indicate these can provide specific interaction and exhibit desirable pharmacokinetic features, paving ways to groundbreaking medicines. On